- Report
- August 2023
- 70 Pages
South Korea
From €4185EUR$4,750USD£3,606GBP
- Report
- March 2019
- 90 Pages
Europe
From €4185EUR$4,750USD£3,606GBP
- Report
- February 2024
- 90 Pages
South Korea
From €4185EUR$4,750USD£3,606GBP
- Report
- February 2024
- 70 Pages
Indonesia
From €4185EUR$4,750USD£3,606GBP
- Report
- February 2024
- 70 Pages
Philippines
From €4185EUR$4,750USD£3,606GBP
- Report
- February 2024
- 70 Pages
India
From €4185EUR$4,750USD£3,606GBP
- Report
- February 2024
- 90 Pages
United States
From €4185EUR$4,750USD£3,606GBP
- Report
- February 2024
- 90 Pages
France
From €4185EUR$4,750USD£3,606GBP
- Report
- February 2024
- 70 Pages
United Kingdom
From €4185EUR$4,750USD£3,606GBP
- Report
- February 2024
- 70 Pages
Russia
From €4185EUR$4,750USD£3,606GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4185EUR$4,750USD£3,606GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4185EUR$4,750USD£3,606GBP
- Report
- February 2024
- 90 Pages
Asia Pacific
From €4185EUR$4,750USD£3,606GBP
- Report
- February 2024
- 80 Pages
Latin America
From €4185EUR$4,750USD£3,606GBP
- Report
- February 2024
- 80 Pages
Europe
From €4185EUR$4,750USD£3,606GBP
- Report
- October 2022
- 70 Pages
Africa
From €4185EUR$4,750USD£3,606GBP
- Report
- May 2023
- 160 Pages
Global
From €4360EUR$4,949USD£3,757GBP

Novorapid is a brand of insulin analogs used to treat endocrine and metabolic disorders. It is a fast-acting insulin that is used to control blood sugar levels in people with diabetes. Novorapid is a recombinant human insulin analog that is produced by recombinant DNA technology. It is designed to act faster and more predictably than regular human insulin. It is used to treat both type 1 and type 2 diabetes. Novorapid is administered subcutaneously and is usually taken before meals. It is used to control postprandial glucose levels and to prevent long-term complications of diabetes.
The Novorapid market is highly competitive, with several companies offering insulin analogs. These include Novo Nordisk, Eli Lilly, Sanofi, Merck, and Boehringer Ingelheim. Each company offers a range of insulin analogs, including Novorapid, to meet the needs of people with diabetes. Show Less Read more